User Name:


remember me

Forgot your password?

Not a member?

Join Now

Press Releases

RSS feedDisplaying articles 1 - 10 of most recent articles

BlitzPredict Launches Online Sports Information Platform Powered by Blockchain Technology With Supreme Court Ruling Enabling U.S. Sports Gambling, Blockchain Ledgers Provide New Level of Transparency as Industry Expands [] | 2 hours, 49 minutes ago | comment? | recommend
Papago! Inc Releases the New GoSafe S810 Papago releases the new GoSafe S810 with a reliable two-channel dash camera providing peace of mind. The S810 will become the discreet and personal witness to all the events unfolding on the road, with cameras facing to the front and rear end. The front c | 3 hours, 23 minutes ago | comment? | recommend
Significant blood sugar improvement with Xultophy 100/3.6 compared to insulin glargine U-100 when used as add-on to oral diabetes medications ORLANDO, Fla., June23, 2018 /PRNewswire/ --Xultophy 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs 1.68% respectively; p0.0001) when
PR Newswire | 3 hours, 44 minutes ago | comment? | recommend
New Data Show Amgen's Repatha (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes THOUSAND OAKS, Calif., June 23, 2018 /PRNewswire/ --Amgen(NASDAQ:AMGN) today announced new data that show Repatha (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-
PR Newswire | 3 hours, 49 minutes ago | comment? | recommend
Investigational Doses of Lilly's Once-Weekly Trulicity (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity (dulaglutide) 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adul
PR Newswire | 3 hours, 49 minutes ago | comment? | recommend
Two-year Data from ViaCyte's STEP ONE Clinical Trial Presented at ADA 2018 SAN DIEGO, June 23, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01 (PEC-Encap) Product Candidate in Type One Diabet
PR Newswire | 3 hours, 49 minutes ago | comment? | recommend
Cloud With Me: Converting Cloud Adoption Into an Accessible Solution for All DUBLIN, June 23, 2018 /PRNewswire/ -- What if businesses could eliminate the complexities of internet based services to improve performance? What if it was possible for employees to work from anywhere, at any time, from any device, and still have a single
PR Newswire | 4 hours, 6 minutes ago | comment? | recommend
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Bi BOULDER, Colo., June 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib,
PR Newswire | 4 hours, 49 minutes ago | comment? | recommend
SPA Selected as a 2018 Washington Post Top Workplace ALEXANDRIA, Va., June 23, 2018 /PRNewswire/ -- For the fifth year in a row, Systems Planning and Analysis, Inc. (SPA), has been named a Top Workplace by The Washington Post. The Washington Post's 2018 Top Workplaces are determined based on feedback collec
PR Newswire | 4 hours, 49 minutes ago | comment? | recommend
Photo from PR Newswire
Xcode Life Announces the South Asian Genome (SAGE) Project CHENNAI, India, June 23, 2018 /PRNewswire/ -- Xcode Life, an innovative personal genomics company has announced the worldwide launch of the South Asian Genome (SAGE) Project. This is open to all individuals with known South Asian roots. All individuals wh
PR Newswire | 5 hours, 49 minutes ago | comment? | recommend